Morgan Stanley assumed coverage of Contineum (CTNM) with an Overweight rating. The firm believes PIPE-791 is competitive in idiopathic pulmonary fibrosis given its optimized pharmacokinetics and for PIPE-791 for primary progressive multiple sclerosis it believes Phase 1b topline results in Q2 can de-risk the Phase 2 study, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM: